Clinicopathological significance of lymphatic vessel density marked by D2-40 and E-cadherin expression in non-small-cell lung cancer

被引:7
|
作者
Jin, Shidai [1 ]
Zhu, Wei [2 ]
Shi, Qifeng [2 ]
Zhang, Zhihong [3 ]
Guo, Renhua [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanjing 210029, Jiangsu, Peoples R China
[2] Peoples Hosp Xishan, Dept Pathol, Wuxi 214011, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing 210029, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Non-small-cell lung cancer; D2-40; Lymphatic vessel density; E-cadherin; BREAST-CANCER; BETA-CATENIN; MICROVESSEL DENSITY; COLORECTAL-CANCER; NODAL METASTASIS; POOR-PROGNOSIS; ALPHA-CATENIN; CARCINOMA; INVASION; TUMORS;
D O I
10.1007/s12032-012-0229-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of our study is to investigate the relationship between lymphatic vessel density (LVD) marked by D2-40 and E-cadherin expression and the clinicopathological characteristics of patients with non-small-cell lung cancer (NSCLC). Immunohistochemical analysis was used to detect the expression of D2-40 and E-cadherin in 46 archival surgical specimens of human NSCLC and 10 cases of benign pulmonary disease. The LVD positively stained with D2-40 was observed and counted. The LVD was mainly distributed in the tumor borderline. The LVD in NSCLC tissues was significantly higher than in benign lesions (p < 0.001), and the LVD marked by D2-40 was significantly associated with lymph node metastasis (p < 0.001). The reduced expression of E-cadherin was present in NSCLC tissues. The positive rate of E-cadherin expression was negatively correlated with TNM stage (p = 0.027), pathological grade (p = 0.032), and lymph node metastasis (p = 0.014), and not significantly correlated with histologic classification (p = 0.714) in NSCLC tissues. A correlation analysis showed that high LVD marked by D2-40 was correlated with reduced E-cadherin expression in NSCLC tissues (t = 36.476, p < 0.001). The new monoclonal antibody D2-40 can specifically recognize lymphatic endothelial cells in NSCLC tissue. The relationship between LVD marked by D2-40 and the reduced expression of E-cadherin and lymph node metastasis in NSCLC was demonstrated. The detection of D2-40 and E-cadherin may be used as an indicator of lymph node metastasis in NSCLC.
引用
收藏
页码:3157 / 3161
页数:5
相关论文
共 50 条
  • [41] Prognostic Value of E-Cadherin Expression in Non-small Cell Lung Cancer Treated With Gefitinib
    Kook, Eun Hee
    Kim, Yeo Myeong
    Kim, Hyeon Tae
    Koh, Jae Soo
    Choi, Yun Jung
    Rho, Jin Kyung
    Kim, Hye-Ryoun
    Kim, Cheol Hyeon
    Lee, Jae Cheol
    ONCOLOGY RESEARCH, 2010, 18 (09) : 445 - 451
  • [42] ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)
    Witta, S. E.
    Dziadziuszko, R.
    Yoshida, K.
    Hedman, K.
    Varella-Garcia, M.
    Bunn, P. A., Jr.
    Hirsch, F. R.
    ANNALS OF ONCOLOGY, 2009, 20 (04) : 689 - 695
  • [43] Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer
    Chen, Xiang-Qi
    Zheng, Li-Xian
    Li, Zhi-Ying
    Lin, Ting-Yan
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2017, 45 (01) : 51 - 58
  • [44] Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer
    Tu, Zegui
    Chen, Xiancheng
    Tian, Tian
    Chen, Guo
    Huang, Meijuan
    AGING-US, 2021, 13 (05): : 7397 - 7415
  • [45] Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression
    Jiang, Wei
    Fan, Hong
    Qian, Cheng
    Ding, Jianyong
    Wang, Qun
    Pang, Xuguang
    BMC CANCER, 2016, 16
  • [46] Expression and clinical significance of Oct-4 and E-cad in non-small-cell lung cancer
    Li, Li
    Lv, Yanling
    Zhang, Ying
    He, Liya
    Zhang, Hongzhen
    ONCOLOGY LETTERS, 2016, 11 (01) : 234 - 236
  • [47] Elevated FUS/TLS expression is negatively associated with E-cadherin expression and prognosis of patients with non-small cell lung cancer
    Xiong, Dian
    Wu, Yong-Bing
    Jin, Chun
    Li, Ji-Jun
    Gu, Jie
    Liao, Yun-Fei
    Long, Xiang
    Zhu, Shu-Qiang
    Wu, Hai-Bo
    Xu, Jian-Jun
    Ding, Jian-Yong
    ONCOLOGY LETTERS, 2018, 16 (02) : 1791 - 1800
  • [48] E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy
    Gkogkou, Pinelopi
    Peponi, Evangelia
    Ntaskagiannis, Dimitrios
    Murray, Samuel
    Demou, Asimo
    Sainis, Ioannis
    Ioakeim, Elli
    Briasoulis, Evangelos
    Tsekeris, Pericles
    IN VIVO, 2020, 34 (01): : 453 - 459
  • [49] Immunohistochemical analysis of the expression of E-cadherin and ZEB1 in non-small cell lung cancer
    Matsubara, Daisuke
    Kishaba, Yuka
    Yoshimoto, Taichiro
    Sakuma, Yuji
    Sakatani, Takashi
    Tamura, Tomoko
    Endo, Shunsuke
    Sugiyama, Yukihiko
    Murakami, Yoshinori
    Niki, Toshiro
    PATHOLOGY INTERNATIONAL, 2014, 64 (11) : 560 - 568
  • [50] Expression and Clinical Significance of Ezrin in Non-Small-Cell Lung Cancer
    Zhang, Xiao-Qin
    Chen, Guo-Ping
    Wu, Tao
    Yan, Jian-Ping
    Zhou, Jian-Ying
    CLINICAL LUNG CANCER, 2012, 13 (03) : 196 - 204